Localisation of pre- and postsynaptic cholinergic markers in the human brain

Behavioural Brain Research

Volumn 221, Issue 2, 2011, Pages 341-355

  Wevers, Andrea ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Acetylcholinesterase (AChE); Choline acetyltransferase (ChAT); Cholinergic transmission; Human brain; Muscarinic acetylcholine receptor (mAChR); Nicotinic acetylcholine receptor (nAChR); Vesicular acetylcholine transporter (VAChT)

Indexed keywords

CHOLINE ACETYLTRANSFERASE; MUSCARINIC RECEPTOR; NICOTINIC RECEPTOR; VESICULAR ACETYLCHOLINE TRANSPORTER;

BINDING SITE; BRAIN CORTEX; BRAIN REGION; BRAIN STEM; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; CORPUS STRIATUM; DIENCEPHALON; ENTORHINAL CORTEX; ENZYME ACTIVITY; ENZYME BINDING; ENZYME LOCALIZATION; FOREBRAIN; HUMAN; IMMUNOREACTIVITY; LIGAND BINDING; NERVE FIBER; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; THALAMUS;

BIOLOGICAL MARKERS; BRAIN; CHOLINERGIC FIBERS; HUMANS; RADIOLIGAND ASSAY; RECEPTORS, MUSCARINIC; RECEPTORS, NICOTINIC; SYNAPTIC MEMBRANES;

EID: 79955729234     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.02.025     Document Type: Review

References (170)

1. Abrams P., Andersson K.-E., Buccafusco J.J., Chapple C., Chet de Groat W., Fryer A.D., et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006, 148:565-578.
2. Adem A., Karlsson E. Muscarinic receptor subtype selective toxins. Life Sci 1997, 60:1069-1076.
3. Alexander SPH, Mathie, A, Peters JA. Acetylcholine (nicotinic). In: Alexander SPH, Mathie, A, Peters JA, editors. Guide to receptors and channels (GRAC). 2nd edition (2007 revision). Br J Pharmacol 2007;150(Suppl 1):S82-3.
4. Alkondon M., Pereira E.F.R., Eisenberg H.M., Albuquerque E.X. Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks. J Neurosci 2000, 20:66-75.
5. Banerjee C., Nyengaard J.R., Wevers A., deVos R.A.I., Jansen-Steur E.N.H., Lindstrom J., et al. Cellular expression of α7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease - a stereological approach. Neurobiol Dis 2000, 7:666-672.
6. Bohnen N.I., Frey K.A. Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders. Mol Imaging Biol 2007, 9:243-257.
7. Bohr I.J., Raya M.A., McIntosh J.M., Chalon S., Guilloteau D., McKeith I.G., et al. Cholinergic nicotinic receptor involvement in movement disorders associated with Lewy body diseases. An autoradiography study using [125I]α-conotoxinMII in the striatum and thalamus. Exp Neurol 2005, 191:292-300.
8. Bordia T., Grady S.R., McIntosh J.M., Quik M. Nigrostriatal damage preferentially decreases a subpopulation of α6β2* nAChRs in mouse, monkey, and Parkinson's disease striatum. Mol Pharmacol 2007, 72:52-61.
9. Bowen D.M., Smith C.B., White P., Davison A.N. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976, 99:459-496.
10. Breese C.R., Adams C., Logel J., Drebing C., Rollins Y., Barnhart M., et al. Comparison of the regional expression of nicotinic acetylcholine receptor alpha7 mRNA and [125I]-alpha-bungarotoxin binding in human post mortem brain. J Comp Neurol 1997, 387:385-398.
11. Burghaus L., Schütz U., Krempel U., de Vos R.A.I., Jansen Steur E.N.H., Wevers A., et al. Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Mol Brain Res 2000, 76:385-388.
12. Cannon D.M., Carson R.E., Nugent A.C., Eckelman W.C., Kiesewetter D.O., Williams J., et al. Reduced muscarinic type2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry 2006, 63:741-747.
13. Chavez-Noriega L.E., Crona J.H., Washburn M.S., Urrutia A., Elliott K.J., Johnson E.C. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors hα2β2, hα2β4, hα3β2, hα3β4, hα4β2, hα4β4, and hα7 expressed in Xenopus oocytes. J Pharmacol Exp Ther 1997, 280:346-356.
14. Cohen R.M., Carson R.E., Filbey F., Szczepanik J., Sunderland T. Age and APOE-epsilon4 genotype influence the effect of physostigmine infusion on the in-vivo distribution volume of the muscarinic-2-receptor dependent tracer [18F]FP-TZTP. Synapse 2006, 60:86-92.
15. Cohen R.M., Podruchny T.A., Bokde A.L., Carson R.E., Herscovitch P., Kiesewetter D.O., et al. Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-epsilon4 allele. Synapse 2003, 49:150-156.
16. Colloby S.J., Pakrasi S., Firbank M.J., Perry E.K., Piggott M.A., Owens J., et al. In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia. NeuroImage 2006, 33:423-429.
17. Conn P.J., Jones C.K., Lindsley C.W. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci 2009, 30:148-155.
18. Cortés R., Probst A., Palacios J.M. Quantitative light microscopic autroadiographic localization of cholinergic muscarinic receptors in human brain: brainstem. Neuroscience 1984, 12:1003-1026.
19. Cortés R., Probst A., Palacidos J.M. Quantitative light microscopic autoradiographic localisation of cholinergic muscarinic receptors in the human brain: forebrain. Neuroscience 1987, 20:65-107.
20. Cortés R., Probst A., Tobler H.-J., Palacios J.M. Muscarinic cholinergic receptor subtypes in the human brain. II. Quantitative autoradiographic studies. Brain Res 1986, 362:239-253.
21. Court J., Clementi F. Distribution of nicotinic subtypes in human brain. Alz Dis Assos Dis 1995, 9(Suppl):6-14.
22. Crook J.M., Dean B., Pavey G., Copolov D. The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. Life Sci 1999, 64:1761-1771.
23. Dani J.A., Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 2007, 47:699-729.
24. Davies P., Maloney A.J.F. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976, 308:1403.
25. Del Mar Arroyo-Jiménez M., Bourgeois J.-P., Marubio L.M., Le Sourd A.-M., Ottersen O.P., Rinvik E., et al. Ultrastructural localization of the α4-subunit of the neuronal acetylcholine nicotinic receptor in the rat substantia nigra. J Neurosci 1999, 19:6475-6487.
26. Dean B., Crook J.M., Pavey G., Opeskin K., Copolov D.L. Muscarinic1 and 2 receptor mRNA in the human caudateputamen: no change in m1 mRNA in schizophrenia. Mol Psych 2000, 5:203-207.
27. Deuther-Conrad W., Patt J.T., Lockman P.R., Allen D.D., Patt M., Schildan A., et al. Norchloro-fluoro-homoepibatidine (NCFHEB) - a promising radioligand for neuroimaging nicotinic acetylcholine receptors with PET. Eur Neuropsychopharma 2008, 18:222-229.
28. Dewey S.I., Volkow N.D., Macgregor R.R., Fowler J.S., Schyler D.J., Brendriem B. Age-related decreases in muscarinic cholinergic receptor binding in the human brain measured with positron emission tomography (PET). J Neurosci Res 1990, 27:569-575.
29. Ding Y.S., Fowler J.S., Logan J., Wang G.J., Telang F., Garza V., et al. 6-[18F]Fluoro-A-85380, a new PET tracer for the nicotinic acetylcholine receptor: studies in the human brain and in vivo demonstration of specific binding in white matter. Synapse 2004, 53:184-189.
30. Duffy A.M., Zhou P., Milner T.A., Pickel V.M. Spatial and intracellular relationships between the alpha7 nicotinic acetylcholine receptor and the vesicular acetylcholine transporter in the prefrontal cortex of rat and mouse. Neuroscience 2009, 161:1091-1103.
31. Eckelman W.C. Imaging of muscarinic receptors in the central nervous system. Curr Pharm Des 2006, 12:3901-3913.
32. Efange M.N. In vivo imaging of the vesicular acetylcholine transporter and the vesicular monoamine transporter. FASEB J 2000, 14:2401-2413.
33. Eggers C., Szelies B., Bauer B., Wienhard K., Schröder H., Herholz K., et al. Imaging of acetylcholine esterase activity in brainstem nuclei involved in regulation of sleep and wakefulness. Eur J Neurol 2007, 14:690-693.
34. Eglen R.M. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol 2006, 26:219-233.
35. Elhusseiny A., Cohen Z., Stanimirovic D., Hamel E. Functional acetylcholine muscarinic receptor subtypes in human brain microcirculation: identification and cellular localization. J Cereb Blood Flow Metab 1999, 19:794-802.
36. Elhusseiny A., Hamel E. Muscarinic but not nicotinic-acetylcholine receptors mediate a nitric oxidedependent dilation in brain cortical arterioles: a possible role for the M5 receptor subtype. J Cereb Blood Flow Metab 2000, 20:298-305.
37. Elliott K.J., Ellis S.B., Berckhan K.J., Urrutia A., Chavez-Noriega L.E., Johnson E.C., et al. Comparative structure of human neuronal α2-α7 and β2-β4 nicotinic acetylcholine receptor subunits and functional expression of the α2, α3, α4, α7, β2, and β4 subunits. J Mol Neurosci 1996, 7:217-228.
38. Fabian-Fine R., Skehel P., Errington M.L., Davies H.A., Sher E., Stewart M.G., et al. Ultrastructural distribution of the alpha7 nicotinic acetylcholine receptor subunit in rat hippocampus. J Neurosci 2001, 21:7993-8003.
39. Fibiger H.C. Cholinergic mechanisms in learning, memory and dementia: a review of the recent evidence. Trends Neurosci 1991, 14:220-223.
40. Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer's disease - the pivotal role of brain M1 receptors. Neurodegener Dis 2008, 5:237-240.
41. Flynn D.D., Ferrari-DiLeo G., Levey A.I., Mash D.C. Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapies. Life Sci 1995, 56:869-876.
42. Flynn D.D., Ferrari-DiLeo G., Mash D.C., Levey A.I. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 1995, 64:1888-1891.
43. Fujita M., Ichise M., van Dyck C.H., Zoghbi S.S., Tamagnan G., Mukhin A.G., et al. Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET. Eur J Nucl Med Mol Imaging 2003, 30:1620-1629.
44. Gallezot J.D., Bottlaender M., Gregoire M.C., Roumenov D., Deverre J.R., Coulon C., et al. In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18F-Fluoro-A-85380 and PET. J Nuc Med 2005, 46:240-247.
45. Geula C., Schatz C.R., Mesulam M.M. Differential localization of NADPH-diaphorase and calbindin-D28k within the cholinergic neurons of the basal forebrain, striatum and brainstem in the rat, monkey, baboon and human. Neurosci 1993, 54:461-476.
46. Gilmor M.L., Erickson J.D., Varoqui H., Hersh L.B., Bennett D.A., Cochran E.J., et al. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 1999, 411:693-704.
47. Gotti C., Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 2004, 74:363-396.
48. Gotti C., Moretti M., Bohr I., Ziabreva I., Vailati S., Longhi R., et al. Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol Dis 2006, 23:481-489.
49. Gotti C., Moretti M., Gaimarri A., Zanardi A., Clementi F., Zoli M. Heterogeneity and complexity of native brain nicotinic receptors. Biochem Pharmacol 2007, 74:1102-1111.
50. Graham A.J., Court J.A., Martin-Ruiz, Jaros E., Perry R., Volsen S.G., et al. Immunohistochemical localisation of nicotinic acetylcholine receptor subunits in human cerebellum. Neuroscience 2002, 113:493-507.
51. Graham A.J., Ray M.A., Perry E.K., Jaros E., Perry R.H., Volsen S.G., et al. Differential nicotinic acetylcholine receptor subunit expression in the human hippocampus. J Chem Neuroanat 2003, 25:97-113.
52. Guan Z.Z., Nordberg A., Mousavi M., Rinne J.O., Hellström-Lindahl E. Selective changes in the levels of nicotinc acetylcholine receptor protein and of corresponding mRNA species in the brains of patients with Parkinson's disease. Brain Res 2002, 956:358-366.
53. Guan Z.Z., Zhang X., Blennow K., Nordberg A. Decreased protein level of nicotinic receptor α7 subunit in the frontal cortex from schizophrenic brain. NeuroReport 1999, 10:1779-1782.
54. Guan Z.Z., Zhang X., Ravid R., Nordberg A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem 2000, 74:237-243.
55. Harrison P.J., Barton A.J.L., Najlerahim A., McDonald B., Pearson R.C.A. Increased muscarinic receptor messenger RNA in Alzheimer's disease temporal cortex demonstrated by in situ hybridization histochemistry. Mol Brain Res 1991, 9:15-21.
56. Hellström-Lindahl E., Gorbounova O., Seiger Å., Mousavi M., Nordberg A. Regional distribution of nicotinic receptors during prenatal development of human brain and spinal cord. Dev Brain Res 1998, 108:147-160.
57. Hellström-Lindahl E., Mousavi M., Zhang X., Ravid R., Nordberg A. Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Mol Brain Res 1999, 66:94-103.
58. Herber D.L., Severance E.G., Cuevas J., Morgan D., Gordon M.N. Biochemical and histochemical evidence of nonspecific binding of alpha7nAChR antibodies to mouse brain tissue. J Histochem Cytochem 2004, 52:1367-1376.
59. Herholz K., Carter F., Jones M. Positron emission tomography imaging in dementia. Br J Radiol 2007, 80:S160-S167.
60. Herholz K., Weisenbach S., Zündorf G., Lenz O., Schröder H., Bauer B., et al. In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease. NeuroImage 2004, 21:136-143.
61. Horti A.G., Gao Y., Kuwabara H., Dannals R.F. Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography. Life Sci 2009, 10.1016/j.lfs.2009.02.029.
62. Horti A.G., Villemagne V.L. The quest for eldorado: development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain. Curr Pharmaceut Des 2006, 12:3877-3900.
63. Hosey M.M. Diversity of structure, signalling and regulation within the family of muscarinic cholinergic receptors. FASEB J 1992, 6:845-852.
64. Iyo M., Namba H., Fukushi K., Shinotoh H., Nagatsuka S., Suhara T., et al. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 1997, 349:1805-1809.
65. Jositsch G., Papadakis T., Haberberger R.V., Wolff M., Wess J., Kummer W. Suitability of muscarinic acetylcholine receptor antibodies for immunohistochemistry evaluated on tissue sections of receptor gene-deficient mice. Naunyn-Schmiedeberg's Arch Pharmacol 2009, 379:389-395.
66. Kadir A., Almkvist O., Wall A., Lângström B., Nordberg A. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl) 2006, 188:509-520.
67. Kadir A., Darreh-Shori T., Almkvist O., Wall A., Lângström B., Nordberg A. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET. Psychopharmacology (Berl) 2007, 191:1005-1014.
68. Kalamida D., Poulas K., Avramopoulou V., Fostieri E., Lagoumintzis G., Lazaridis K., et al. Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity. FEBS 2007, 274:3799-3845.
69. Kasashima S., Kawashima A., Muroishi Y., Futakuchi H., Nakanishi I., Oda Y. Neurons with choline acetyltransferase immunoreactivity and mRNA are present in the human cerebral cortex. Histochem Cell Biol 1999, 111:197-207.
70. Kasashima S., Muroishi Y., Futakuchi H., Nakanishi I., Oda Y. In situ hybridization study of the distribution of choline acetyltransferase in the human brain. Brain Res 1998, 806:8-15.
71. Kimes A.S., Chefer S.I., Matochik J.A., Contoreggi C., Vaupel D.B., Stein E.A., et al. Quantification of nicotinic acetylcholine receptors in the human brain with PET: bolus plus infusion administration of 2-[18F]F-A85380. Neuroimage 2008, 39:717-727.
72. Kimes A.S., Horti A.G., London E.D., Chefer S.I., Contoreggi C., Ernst M., et al. 2-[18F]F-A85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. FASEB J 2003, 17:1331-1333.
73. Kirkpatrick P. Technology: specificity concerns with antibodies for receptor mapping. Nat Rev Drug Discov 2009, 8:278-1278.
74. Krenz I., Kalkan D., Wevers A., de Vos R.A.I., Jansen Steur E.N.H., Lindstrom J., et al. Parvalbumin-containing interneurons of the human cerebral cortex express nicotinic acetylcholine receptor proteins. J Chem Neuroanat 2001, 21:239-246.
75. Kuhl D.E., Koeppe R.A., Fessler J.A., Minoshima S., Ackermann R.J., Carey J.E., et al. In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM. J Nucl Med 1994, 35:405-410.
76. Kuhl D.E., Koeppe R.A., Minoshima S., Snyder S.E., Ficaro E.P., Foster N.L., et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 1999, 52:691-699.
77. Kuhl D.E., Koeppe R., Snyder S., Minoshima S., Frey K., Kilbourn M. Mapping acetylcholinesterase activity in human brain uising PET and N-[11C]Methylpiperidinyl propionate (PMP). J Nucl Med 1996, 37(Suppl):21P.
78. Lang W., Henke H. Cholinergic receptor binding and autoradiography in brains of non-neurological and senile dementia of Alzheimer type patients. Brain Res 1983, 267:271-280.
79. Levey A.I., Edmunds S.M., Hersch S.M., Wiley R.G., Heilmann C.J. Light and electron microscopic study of m2 muscarinic acetylcholine receptor in the basal forebrain of the rat. J Comp Neurol 1995, 351:339-356.
80. Lindstrom J. The structures of neuronal nicotinic receptors. Handbook of experimental pharmacology 2000, 101-162. Springer, Berlin. F. Clementi, D. Fornasari, C. Gotti (Eds.).
81. Lundqvist H., Nordberg A., Hartvig P., Lângström B. (S)-(-)-[11C]-nicotine binding assessed by PET: a dual tracer model evaluated in the rhesus monkey brain. Alzheimer Dis Assoc Disord 1998, 12:238-246.
82. Mamede M., Ishizu K., Ueda M., Mukai T., Iida Y., Fukuyama H., et al. Quantification of human nicotinic acetylcholine receptors with 123I-5IA SPECT. J Nucl Med 2004, 45:1458-1470.
83. Martin-Ruiz C.M., Court J.A., Lee M., Piggott M., Johnson M., Ballard C., et al. Nicotinic receptors in dementia of Alzheimer, Lewy body and vascular types. Acta Neurol Scand 2000, 176(Suppl):34-41.
84. Martin-Ruiz C.M., Lawrence S., Piggott M., Kuryatov A., Lindstrom J., Gotti C., et al. Nicotinic receptors in the putamen of patients with dementia with Levy bodies and Parkinson's disease: relation to changes in α-synuclein expression. Neurosci Lett 2002, 335:134-138.
85. Marutle A., Warpman U., Bogdanovic N., Nordberg A. Regional distribution of subtypes of nicotinic receptors in human brain and effect of aging studied by (+)-[3H]epibatidine. Brain Res 1998, 801:143-149.
86. Mash D.C., Flynn D.D., Potter L.T. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 1985, 228:1115-1117.
87. McCann C.M., Bracamontes J., Steinbach J.H., Sanes J.R. The cholinergic antagonist α-bungarotoxin also binds and blocks a subset of GABA receptors. Proc Natl Acad Sci USA 2006, 103:5149-5154.
88. Mesulam M.-M. The cholinergic contribution to neuromodulation in the cerebral cortex. Semin Neurosci 1995, 7:297-307.
89. Mesulam M.-M., Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J Comp Neurol 1988, 275:216-240.
90. Mesulam M.-M., Geula C. Overlap between acetylcholinesterase-rich and choline acetyltransferase-positive (cholinergic) axons in human cerebral cortex. Brain Res 1992, 577:112-120.
91. Mesulam M.-M., Geula C., Bothwell M.A., Hersh L.B. Human reticular formation: cholinergic neurons of the pedunculopontine and laterodorsal tegmental nuclei and some cytochemical comparisons to forebrain cholinergic neurons. J Comp Neurol 1989, 281:611-633.
92. Mesulam M.-M., Geula C., Cosgrove R., Mash D., Brimijoin S. Immunocytochemical demonstration of axonal and perikaryal acetylcholinesterase in human cerebral cortex. Brain Res 1991, 539:233-238.
93. Mesulam M.-M., Hersh L.B., Mash D.C., Geula C. Differential cholinergic innervation within functional subdivisions of the human cerebral cortex: a choline acetyltransferase study. J Comp Neurol 1992, 318:316-328.
94. Mesulam M.-M., Mash D., Hersh L.B., Bothwell M., Geula C. Cholinergic innervation of the human striatum, globus pallidus, subthalamic nucleus, substantia nigra, and red nucleus. J Comp Neurol 1992, 323:252-268.
95. Michel M.C., Wieland T., Tsujimoto G. How reliable are G-protein-coupled receptor antibodies?. Naunyn-Schmied Arch Pharmacol 2009, 379:385-388.
96. Mitsis E.M., Reech K.M., Bois F., Tamagnan G.D., Macavoy M.G., Seibyl J.P., et al. 123I-5-IA-85380 SPECT imaging of nicotinic receptors in Alzheimer disease and mild cognitive impairment. J Nucl Med 2009, 50:1455-1463.
97. Mizukawa K., McGeer P.L., Tago H., Peng J.H., McGeer E.G., Kimura H. The cholinergic system of the human hindbrain studied by choline acetyltransferase immunohistochemistry and acetylcholinesterase histochemistry. Brain Res 1986, 379:39-55.
98. Mohammed A.H. Effects of cholinesterase inhibitors on learning and memory in rats: a brief review with special reference to THA. Acta Neurol Scand Suppl 1993, 149:13-15.
99. Moser N., Mechawar N., Jones I., Gochberg-Sarver A., Orr-Urtreger A., Plomann M., et al. Evaluating the suitability of nicotinic acetylcholine receptor antibodies for standard immunodetection procedures. J Neurochem 2007, 102:479-492.
100. Mousavi M., Hellström-Lindahl E., Guan Z.-Z., Shan K.-R., Ravid R., Nordberg A. Protein and mRNA levels of nicotinic receptors in brain of tobacco using controls and patients with Alzheimer's disease. Neuroscience 2003, 122:515-520.
101. Mufson E.J., Bothwell M., Hersh L.B., Kordower J.H. Nerve growth factor receptor immunoreactive profiles in the normal, aged human basal forebrain: colocalization with cholinergic neurons. J Comp Neurol 1989, 285:196-217.
102. Mufson E.J., Ginsberg S.D., Ikonomovic M.D., DeKosky S.T. Human cholinergic forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat 2003, 26:233-242.
103. Mufson E.J., Jaffar S., Levey A.I. m2 muscarinic acetylcholine receptor-immunoreactive neurons are not reduced within the nucleus basalis in Alzheimer's disease: relationship with cholinergic and galaninergic perikarya. J Comp Neurol 1998, 392:313-329.
104. Müller-Gärtner H.W., Wilson A.A., Dannals R.F., Wagner H.N., Frost J.J. Imaging muscarinic cholinergic receptors in human brain in vivo with Spect, [123I]4-iododexetimide, and [123I]4-iodolevetimide. J Cereb Blood Flow Metab 1992, 12:562-570.
105. Nâgren K, Halldin C, Rinne JO. Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease. Eur J Nucl Med Mol Imaging, doi:10.1007/s00259-009-1301-z.
106. Namba H., Iyo M., Fukushi K., Shinotoh H., Nagatsuka S., Suhara T., et al. Human cerebral acetylcholinesterase activity measured with positron emission tomography procedure, normal values and effect of age. Eur J Nucl Med Mol Imaging 1999, 26:135-143.
107. Nathanson N.M. Synthesis and trafficking, and localization of muscarinic acetylcholine receptors. Pharmacol Ther 2008, 119:33-43.
108. Norbury R., Travis M.J., Erlandsson K., Waddington W., Owens J., Pimlott S., et al. In vivo imaging of muscarinic receptors in the aging female brain with (R,R)[123I]-I-QNB and single photon emission tomography. Exp Gerontol 2005, 40:137-145.
109. Nordberg A. Molecular imaging markers in clinical trials in Alzheimer's disease. J Nutrition Health Aging 2009, 4:346-347.
110. Nordberg A., Lilja A., Lundqvist H., Hartvig P., Amberla K., Viitanen M., et al. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. Neurobiol Aging 1992, 13:747-758.
111. Nordberg A., Lundqvist H., Hartvig P., Andersson J., Johansson M., Hellström-Lindahl E., et al. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment. Dement Geriatr Cogn Disord 1997, 8:78-84.
112. Nordberg A., Lundqvist H., Hartvig P., Lilja A., Langstrom B. Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains: in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord 1995, 9:21-27.
113. Oda Y. Choline acetyltransferase: the structure, distribution and pathologic changes in the central nervous system. Pathol Int 1999, 49:921-937.
114. Ogawa M., Tsukada H., Hatano K., Ouchi Y., Saji H., Magata Y. Central in vivo nicotinic acetylcholine receptor imaging agents for positron emission tomography (PET) and single photon emission computed tomography (SPECT). Biol Pharm Bull 2009, 32:337-340.
115. Pappata S., Tavitian B., Traykov L., Jobert A., Dalger A., Mangin J.F., et al. In vivo imaging of human cerebral acetylcholinesterase. J Neurochem 1996, 67:876-879.
116. Pascual J., González A.M., Pazos A. Autoradiographic distribution of [3H]hemicholinium-3 binding sites in human brain. Brain Res 1989, 505:306-310.
117. Pascual J., González A.M., Pazos A. Characterization of [3H]hemicholinium-3 binding sites in human brain membranes: a marker for presynaptic cholinergic nerve terminals. J Neurochem 1990, 54:792-800.
118. Perry E.K., Kilford L., Lees A.J., Burn D.J., Perry R.H. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 2003, 54:235-238.
119. Perry E.K., Lee M.L.W., Martin-Ruiz C.M., Court J.A., Volsen S.G., Merrit J., et al. Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry 2001, 158:1058-1066.
120. Piggott M.A., Owens J., O'Brien J., Colloby S., Fenwick J., Wyper D., et al. Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease. J Chem Neuroanat 2003, 25:161-173.
121. Piggott M., Owens J., O'Brien J., Paling S., Wyper D., Fenwick J., et al. Comparative distribution of binding of the muscarinic receptor ligands pirenzepine, AF-DX 384, (R,R)-I-QNB and (R,S)-I-QNB to human brain. J Chem Neuroanat 2002, 24:211-223.
122. Pimlott S.L., Piggott M., Owens J., Greally E., Court J.A., Jaros E., et al. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: In vitro binding study using 5-[125I]-A-85380. Neuropsychopharmacol 2004, 29:108-116.
123. Podruchny T.A., Connolly C., Bokde A., Herscovitch P., Eckelman W.C., Kiesewetter D.O., et al. In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. Synapse 2003, 48:39-44.
124. Pradidarcheep W., Stallen J., Labruyère W.T., Dabhoiwala N.F., Michel M.C., Lamers W.H. Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors. Naunyn-Schmied Arch Pharmacol 2009, 379:397-402.
125. Quik M., Bordia T., Forno L., McIntosh L.M. Loss of α-conotoxinMII- and A85380-sensitive nicotinic receptors in Parkinson's disease striatum. J Neurochem 2004, 3:668-679.
126. Quik M., Huang L., Parameswaran N., Bordia T., Campos C., Perez X.A. Multiple roles for nicotine in Parkinson's disease. Biochem Pharmacol 2009, 78:677-685.
127. Quiron R., Aubert I., Lapchak P.A., Schaum R.P., Teolis S., Gauthier S., et al. Muscarinic receptor subtypes in human neurodegenerative disorders: focus on Alzheimer's disease. Trends Pharmacol Sci 1989, (Suppl):80-84.
128. Raedler T.J., Knable M.B., Jones D.W., Urbina R.A., Gorey J.G., Lee K.S., et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 2003, 160:118-127.
129. Ravasi L., Kiesewetter D.O., Shimoji K., Lucignani G., Eckelmann W.C. Why does the agonist [(18)F]FP-TZTP bind preferentially to the M(2) muscarinic receptor?. Eur J Nucl Med Mol Imaging 2006, 33:292-300.
130. Ray M., Bohr I., McIntosh J.M., Ballard C., McKeith I., Chalon S., et al. Involvement of α6/α3 neuronal nicotinic acaetylcholine receptors in neuropsychiatric features of dementia with Lewy bodies: [125I]-α-conotoxin MII binding in the thalamus and striatum. Neurosci Lett 2004, 220-225.
131. Rodriguez-Puertas R., Pascual J., Vilaro T., Pazos A. Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease. Synapse 1997, 26:341-350.
132. Rouse S.T., Thomas T.M., Levey A.I. Muscarinic acetylcholine receptor subtype, m2: diverse functional implications of differential synaptic localization. Life Sci 1997, 60:1031-1038.
133. Rubboli F., Court J.A., Sala C., Morris C., Chini B., Perry E., et al. Distribution of nicotinic receptors in the human hippocampus and thalamus. Eur J Neurosci 1994, 6:1596-1604.
134. Salah-Uddin H., Thomas D.R., Davies C.H., Hagan J.J., Wood M.D., Watson J.M., et al. Pharmacological assessment of M1 muscarinic acetylcholine receptor-Gq/11 protein coupling in membranes prepared from post mortem human brain tissue. J Pharmacol Exp Ther 2008, 325:869-874.
135. Scarr E., Sundram S., Keriakous D., Dean B. Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. Biol Psychiatry 2007, 61:1161-1170.
136. Schäfer M.K., Weihe E., Erickson J.D., Eiden L.E. Human and monkey cholinergic neurons visualized in paraffin-embedded tissues by immunoreactivity for VAChT, the vesicular acetylcholine transporter. J Mol Neurosci 1996, 6:225-235.
137. Schröder H., Zilles K., Luiten P.G.M., Strosberg A.D., Aghchi A. Human cortical neurons contain both nicotinic and muscarinic acetylcholine receptors: an immunocytochemical double-labeling study. Synapse 1989, 4:319-326.
138. Schröder H., Zilles K., Luiten P.G.M., Strosberg A.D. A. Immunocytochemical visualization of muscarinic cholinoceptors in the human cerebral cortex. Brain Res 1990, 514:249-258.
139. Schröder H., Zilles K., Maelicke A., Hajós F. Immunohisto- and cytochemical localization of cortical nicotinic cholinoceptors in rat and man. Brain Res 1989, 502:287-295.
140. Seeger T., Fedorova I., Zheng F., Miyakawa T., Koustova E., Gomeza J., et al. M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity. J Neurosci 2004, 24:10117-10127.
141. Sheffler D.J., Williams R., Bridges T.M., Xiang Z., Kane A.S., Byun N.E., et al. A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. Mol Pharmacol 2009, 76:356-368.
142. Shiozaki K., Iseki E., Hino H., Kosaka K. Distribution of m1 muscarinic acetylcholine receptors in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies - an immunohistochemical study. J Neurol Sci 2001, 193:23-28.
143. Shiozaki K., Iseki E., Uchiyama H., Watanabe Y., Haga T., Kameyama K., et al. Alterations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: relation to Alzheimer's disease. J Neurol Neurosurg Psychiatry 1999, 67:209-213.
144. Sihver W., Gillberg P.G., Nordberg A. Laminar distribution of nicotinic receptor subtypes in human cerebral cortex as determined by [3H](-)nicotine, [3H]cytisine and [3H]epibatidine in vitro autoradiography. Neuroscience 1998, 85:1121-1133.
145. Smiley J.F., Morelli F., Mesulam M.M. Cholinergic synapses in human cerebral cortex: an ultrastructural study in serial sections. Exp Neurol 1997, 144:361-368.
146. Sparks D.L., Beach T.G., Lukas R.J. Immunohistochemical localization of nicotinic β2 and α4 receptor subunits in normal human brain and individuals with Lewy body and Alzheimer's disease: preliminary observations. Neurosci Lett 1998, 256:151-154.
147. Spurden D.P., Court J.A., Lloyd S., Oakley A., Perry R., Pearson C., et al. Nicotinic receptor distribution in the human thalamus: autoradiographical localization of [3H]nicotine and [125I] alpha-bungarotoxin binding. J Chem Neuroanat 1997, 13:105-113.
148. Sudo Y., Suhara T., Honda Y., Nakajima T., Okubo Y., Suzuki K., et al. Muscarinic cholinergic receptors in human narcolepsy: a PET study. Neurology 1998, 51:1297-1302.
149. Sunderland T., Esposito G., Molchan S.E., Coppola R., Jones D.W., Gorey J., et al. Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine: a SPECT study. Psychopharmacology 1995, 12:231-241.
150. Teaktong T., Piggott M.A., McKeith I.G., Perry R.H., Ballard C.G., Perry E.K. Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies. Behav Brain Res 2005, 161:299-305.
151. Terzano S., Court J.A., Fornasari D., Griffiths M., Spurden D.P., Lloyd S., et al. Expression of the alpha 3 nicotinic receptor subunit mRNA in aging and Alzheimer's disease. Mol Brain Res 1998, 63:72-78.
152. Tohgi H., Utsugisawa K., Yoshimura M., Nagane Y., Mihara M. Age-related changes in nicotinic acetylcholine receptor subunits alpha4 and beta2 messenger RNA expression in post mortem human frontal cortex and hippocampus. Neurosci Lett 1998, 245:139-142.
153. Tohgi H., Utsugisawa K., Yoshimura M., Nagane Y., Mihara M. Alterations with aging and ischemia in nicotinic acetylcholine receptor subunits alpha4 and beta2 messenger RNA expression in post mortem human putamen. Implications for susceptibility to parkinsonism. Brain Res 1998, 791:186-190.
154. Toyohara J., Sakata M., Wu J., Ishikawa M., Oda K., Ishii K., et al. Preclinical and the first clinical studies on [11C]CHIBA-1001 for mapping alpha7 nicotinic receptors by positron emission tomography. Ann Nucl Med 2009, 23:301-309.
155. Tu Z., Efange S.M.N., Xu J., Li S., Jones L.A., Parsons S.M., et al. Synthesis and in vitro and in vivo evaluation of 18F-labeled positron emission tomography (PET) ligands for imaging the vesicular acetylcholine transporter. J Med Chem 2009, 52:1358-1369.
156. Tzavara E.T., Bymaster F.P., Felder C.C., Wade M., Gomeza J., Wess J., et al. Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol Psychiatry 2003, 8:673-679.
157. Utsugisawa K., Nagane Y., Tohgi H., Yoshimura M., Ohba H., Genda Y. Changes with aging and ischemia in nicotinic acetylcholine receptor subunit alpha7 mRNA expression in post mortem human frontal cortex and putamen. Neurosci Lett 1999, 270:145-148.
158. van der Zee, Luiten P.G. Muscarinic acetylcholine receptors in the hippocampus, neocortex and amygdala: a review of immunocytochemical localization in relation to learning and memory. Prog Neurobiol 1999, 58:409-471.
159. van Osten E.M., Wilson A.A., Stephenson K.A., Mamo D.C., Pollock B.G., Mulsant B.H., et al. An improved radiosynthesis of the muscarinic M2 radiopharmaceutical, [18F]FP-TZTP. Appl Radiat Isot 2009, 67:611-616.
160. Wevers A., Jeske A., Lobron Ch, Birtsch Ch, Heinemann S., Maelicke A., et al. Cellular distribution of nicotinic acetylcholine receptor subunit mRNAs in the human cerebral cortex as revealed by non-isotopic in situ hybridization. Mol Brain Res 1994, 25:122-128.
161. Wevers A., Monteggia L., Nowacki S., Bloch W., Schütz U., Lindstrom J., et al. Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease - histotopographical correlation with amyloid plaques and hyperphosphorylated tau-protein. Eur J Neurosci 1999, 11:2551-2565.
162. Wevers A., Sullivan J.P., Giordano T., Birtsch C., Monteggia L.M., Nowacki S., et al. Cellular distribution of the mRNA for the α7 subunit of the nicotinic acetylcholine receptor in the human cerebral cortex. Drug Dev Res 1995, 36:103-110.
163. Whiting P.J., Lindstrom J.M. Characterization of bovine and human neuronal nicotinic acetylcholine receptors using monoclonal antibodies. J Neurosci 1988, 8:3395-3404.
164. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci 1997, 20:92-98.
165. Xie G., Gunn R.N., Dagher A., Daloze T., Plourde G., Backman S.B., et al. PET quantification of muscarinic cholinergic receptors with [N-11C-methyl]-benztropine and application to studies of propofol-induced unconsciousness in healthy human volunteers. Synapse 2004, 51:91-101.
166. Yoshida T., Kuwabara Y., Sasaki M., Fukumura T., Ichimiya A., Takita M., et al. Sex-related differences in the muscarinic acetylcholinergic receptor in the healthy human brain - a positron emission tomography study. Ann Nucl Med 2000, 14:97-101.
167. Zhang W., Basile A.S., Gomeza J., Volpicelli L.A., Levey A.I., Wess J. Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J Neurosci 2002, 22:1709-1717.
168. Zhou Y., Brasic J.R., Musachio J.L., Zukin S.R., Kuwabara H., Crabb A.H., et al. Human [123I]5-I-A-85380 dynamic spect studies in normals: kinetic analysis and parametric imaging. Proc IEEE Nucl Sci Symposium and Med Imaging 2001, 1335-1340.
169. Zubieta J.K., Koeppe R.A., Mulholland G.K., Kuhl D.E., Frey K.A. Quantification of muscarinic cholinergic receptors with [11C]NMPB and positron emission tomography: method development and differentiation of tracer delivery from receptor binding. J Cereb Blood Flow Metab 1998, 18:619-631.
170. Zubieta J.K., Koeppe R.A., Frey K.A., Kilbourn M.R., Mangner T.J., Foster N.L., et al. Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET. Synapse 2001, 39:275-287.